Strong growth and recruitments required more office space


Immedica Pharma AB, a pharmaceutical company focused on commercialization of rare and specialty diseases has recently moved its head quarter to the newly established Life City near Torsplan in Stockholm. Immedica is one of several pharmaceutical companies that are located at the new facilities on Solnavägen.

According to a report from Stockholms Handelskammare1, the Life Science sector in Stockholm-Uppsala is highly significant for the labour market and employs more than 21 000 people in the region. The Swedish Government’s life science strategy is to make Sweden a leading life science nation and the Stockholm region has the objective that Stockholm should be one of the world’s five leading life science regions in 2025.

Immedica’s CEO Anders Edvell comments “Moving our head quarter to the facilities at Life city is a milestone for the company. Since the start in May 2018, we have grown more than tenfold in terms of number of employees. It has been a fantastic journey so far and the new location will be important for our continued growth. Together with our peers in the sector we are happy to be contributing to the positioning of Stockholm as a leading life science region.”


About Immedica Pharma
Immedica is a fast-growing private niche pharma group. Its headquarter is based in Stockholm, Sweden, and it has commercial coverage across Europe and the Middle East.

Immedica provides significant know-how and experience from commercialization of niche/specialty care products across Europe and the Middle East, and the company’s management team has an outstanding track record of operating niche pharma products internationally. Immedica has capabilities to provide optimal access of specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, quality and product distribution.

Immedica’s main owner is Impilo AB, a private Nordic investment company established in 2017, with more than SEK 3.6 billion in committed capital from leading Nordic and international investors.